Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation-Reference-Cited by-同舟云学术

Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation

Published:2021-05-25 Issue:2 Volume:57 Page:347-360
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Antos Nicholas J.¹²^ORCID,Savant Adrienne P.³⁴^ORCID

Affiliation:

1. Department of Pediatrics, Division of Pulmonary and Sleep Medicine Medical College of Wisconsin Milwaukee Wisconsin USA

2. Department of Pediatric Pulmonology Children's Wisconsin Milwaukee Wisconsin USA

3. Department of Pediatrics Children's Hospital of New Orleans New Orleans Louisiana USA

4. Department of Pediatrics Tulane University New Orleans Louisiana USA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.25459

Reference99 articles.

1. Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report. 2020.https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf

2. Quality improvement initiative to improve pulmonary function in pediatric cystic fibrosis patients

3. Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007‐2016

4. Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis

5. Variation in lung function and nutritional decline in cystic fibrosis by genotype: An analysis of the Canadian cystic fibrosis registry

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced pulmonary drug delivery formulations for the treatment of cystic fibrosis;Drug Discovery Today;2023-10

2. Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0;Respiratory Medicine and Research;2023-06

3. Future therapies for cystic fibrosis;Nature Communications;2023-02-08

4. Novel Substituted Cyclopropyl Compounds as CFTR Modulators for Treating Cystic Fibrosis;ACS Medicinal Chemistry Letters;2022-09-06

5. Novel Macrocyclic 1,3,4-Oxadiazoles as CFTR Modulators for Treating Cystic Fibrosis;ACS Medicinal Chemistry Letters;2022-06-30